Corcept Therapeutics (NASDAQ:CORT) Stock Gets Downgrade from Zacks Research

Posted by Geri Gentry on Oct 29th, 2026

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Other equities analysts have also recently issued research reports about the company. Truist Financial initiated coverage on Corcept Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price target for the company. Wall Street Zen upgraded shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 1st. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Corcept Therapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $138.17.

Get Our Latest Stock Report on CORT

Corcept Therapeutics Price Performance

Shares of CORT opened at $86.28 on Tuesday. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $126.38. The stock’s 50-day moving average is $113.44 and its two-hundred day moving average is $74.16. The stock has a market cap of $9.33 billion, a PE ratio of 205.43 and a beta of 0.40.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million during the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%. The company’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 earnings per share. On average, research analysts anticipate that Corcept Therapeutics will post 1.83 earnings per share for the current year.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director Kimberly Park sold 26,685 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $122.55, for a total transaction of $3,270,246.75. Following the sale, the director directly owned 30,000 shares in the company, valued at $3,676,500. The trade was a 47.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Guyer sold 16,300 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $113.43, for a total value of $1,848,909.00. Following the sale, the insider owned 3,985 shares in the company, valued at $452,018.55. This represents a 80.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 374,748 shares of company stock valued at $43,609,410 in the last three months. 20.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CORT. BlackRock Inc. bought a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at approximately $1,080,964,000. Parallel Advisors LLC lifted its stake in Corcept Therapeutics by 2.5% during the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock worth $160,329,000 after purchasing an additional 96,763 shares during the last quarter. First Trust Advisors LP lifted its stake in Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Corcept Therapeutics during the second quarter worth $49,185,000. Finally, Bank of America Corp DE acquired a new position in Corcept Therapeutics in the second quarter worth $28,569,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a commercial-stage biopharmaceutical company focused on developing medicines that selectively modulate the glucocorticoid receptor. The company’s research is based on the role of excess cortisol in metabolic, psychiatric, oncologic and other serious medical conditions.

Corcept’s primary marketed product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.